Reviva Pharma (NASDAQ: RVPH) Charting Success: Reviva Pharma's Journey from phase 3 to Potential NDA filing

Reviva (Nasdaq: RVPH) is a Phase 3 clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva's current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva's pipeline currently has two drug candidates, RP5063 (Brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Topline data for pivotal Phase 3 trial evaluating brilaroxazine for the treatment of schizophrenia remains on track for Q3 2023. Reviva has been granted composition of matter patents for both RP5063 and R1208 in the US, Europe, and several other countries. Learn more at RVPHinfo.com. RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time.   Reviva Pharmaceuticals Holdings Inc. (RVPH) is a client of RedChip Companies, Inc. RVPH agreed to pay RedChip Companies, Inc. an $11,000 per month cash fee for 12 months of RedChip investor awareness services. The CEO of RedChip owns 8,553 shares of RVPH. RVPH also agreed to pay RedChip an eighty-thousand dollar cash fee for two multi-week national TV ad campaigns scheduled for December 13 to December 29, 2023 and March 15 to April 3, 2024.   For full disclosure, visit RedChip.com/disclosures.